GSK plc has witnessed a
40% rally in December 2025, driven by successful buybacks, a new CEO and Q3 results. The investment of
$30 Billion in the US has heightened market focus, and an ongoing share buyback program continues to enhance shareholder value.
Vaccine breakthroughs have caused GSK shares to surge by 31% in 2025 and the FDA's Orphan Drug Tag for
GSK's Risvutatug Rezetecan further bolsters GSK's strength. Recent advancements are reshaping GSK's story, with
Arexvy's EU expansion,
Blujepa's FDA approval, and analyst forecasts becoming focal points. Positive revision in FY25 growth outlook due to the surge in
Q3 Pre-tax profit validates GSK's growth potential. However, the firm faces challenges due to narrowing approval of a blood cancer drug which limits its US relaunch and an ongoing legal battle with AnaptysBio over a cancer drug license.
GSK Stocks News Analytics from Wed, 18 Jun 2025 07:00:00 GMT to Sat, 13 Dec 2025 18:01:48 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
